Supplemental material
Open access
7,668
Views
5
CrossRef citations to date
0
Altmetric
Meta-analysis
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis
Karissa Johnstona Broadstreet Health Economics & Outcomes Research, Vancouver, BC, CanadaCorrespondence[email protected]
View further author information
, View further author information
Evan Popoffa Broadstreet Health Economics & Outcomes Research, Vancouver, BC, CanadaView further author information
, Alison Deightona Broadstreet Health Economics & Outcomes Research, Vancouver, BC, CanadaView further author information
, Parisa Dabirvaziria Broadstreet Health Economics & Outcomes Research, Vancouver, BC, CanadaView further author information
, Linda Harrisb Biohaven Pharmaceuticals, New Haven, CT, USAView further author information
, Alexandra Thiryb Biohaven Pharmaceuticals, New Haven, CT, USAView further author information
, Robert Croopb Biohaven Pharmaceuticals, New Haven, CT, USAView further author information
, Vladimir Coricb Biohaven Pharmaceuticals, New Haven, CT, USAView further author information
, Gilbert L’Italienb Biohaven Pharmaceuticals, New Haven, CT, USAView further author information
& James Morenc Island Hospital, Anacortes, Washington, USAView further author information
show all
Pages 155-166
|
Received 13 Apr 2021, Accepted 16 Jun 2021, Published online: 02 Jul 2021
Related Research Data
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis
Source:
Taylor & Francis
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.